UNSPSC 51321501: Eniclobrate

This classification denotes an anti-lipidemic agent with the molecular formula C24H24ClNO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier M469UFX48N, chemically known as butanoic acid, 2-(4-((4-chlorophenyl)methyl)phenoxy)-2-methyl-, 3-pyridinylmethyl ester, (+-)- but generally known as eniclobrate, which bears US NIH Compound Identifier 43387. European Medicines Agency schedules Eniclobrate in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06532MIG.

UNSPSC 51321501 Eniclobrate, a Commodity code, represents pharmaceutical supply procurement for emergency medical services and state health programs. State and local governments buy this code's scope as finished pharmaceuticals for emergency response, hospital formularies, and Medicaid programs — specifically injectable medications such as epinephrine, labetalol, adenosine, and diltiazem used in advanced life support protocols, as well as generic multi-source pharmaceuticals and over-the-counter products distributed through state health benefit systems. Issuing bodies include municipal fire-rescue departments, state health agencies, cooperative purchasing alliances, and Medicaid programs. Recent solicitations show activity from the City of Tampa's Purchasing Department procuring for its fire rescue service, the Texas Health and Human Services Commission conducting strategic market research on direct-to-manufacturer prescription models, and the Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) coordinating multi-state generic pharmaceutical supply agreements that include Oregon participation.

Activity clusters in Florida, Texas, and Minnesota, with multi-state reach through cooperative purchasing vehicles. The City of Tampa issued an IFB (Bid No. 26-P-00188) in April 2026 with a response date of April 8, 2026, for advanced life support medications valued at $40,000, requiring delivery within ten calendar days and 365-day warranties on all materials; this bid included a 5 percent Small Local Business Enterprise (SLBE) discount and required OSHA Safety Data Sheets and WCAG 2.2 accessibility documentation. MMCAP issued an RFP (S1070000015802) with a March 26, 2026 deadline for generic multi-source pharmaceuticals and OTC products to be supplied through three authorized wholesalers (Cencora, Cardinal Health, Morris & Dickson), emphasizing price competitiveness (75 percent of evaluation weight), cGMP and Drug Supply Chain Security Act compliance, and a two-year contract term with optional extensions through June 30, 2028. The Texas HHS Commission posted an RFI (HHS0017013) in April 2026 to gather vendor capabilities for implementing a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager arrangements, signaling future formal solicitations for state-managed pharmaceutical procurement restructuring.